Jade Biosciences (JBIO) Stock Statistics & Valuation Metrics

Jade Biosciences has a market cap or net worth of $926.61M. The enterprise value is $895.97M.

Market Cap

$926.61M

Enterprise Value

$895.97M

Jade Biosciences has 63,597,385 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

63,597,385

Owned by Insiders

8.01%

Owned by Institutions

35.38%

Jade Biosciences’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -34.07%.

Return on Equity (ROE)

-0.38

Return on Assets (ROA)

-0.36

Return on Invested Capital (ROIC)

-34.07%

Return on Capital Employed (ROCE)

-0.34

Revenue Per Employee

0

Profits Per Employee

-2.32M

Employee Count

55

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Jade Biosciences is -5.13. Jade Biosciences’s PEG ratio is -0.02.

PE Ratio

-5.13

PS Ratio

0.00

PB Ratio

1.96

Price to FCF

-7.26

Price to Operating Cash Flow

-6.97

PEG Ratio

-0.02

In the last 12 months, Jade Biosciences had revenue of 0 and earned -127.41M in profits. Earnings per share was -4.06.

Revenue

0

Gross Profit

0

Operating Income

-113.54M

Pretax Income

-127.35M

Net Income

-127.41M

EBITDA

-127.33M

Earnings Per Share (EPS)

-4.06

In the last 12 months, operating cash flow was -123.51M and capital expenditures -60,000, giving a free cash flow of -123.57M billion.

Operating Cash Flow

-123.51M

Free Cash Flow

-123.57M

Free Cash Flow per Share

-2.02

Jade Biosciences pays an annual dividend of $2.40, resulting in a dividend yield of ―

Dividend Per Share

$2.40

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-13.79%

Earnings Yield

-17.81%

Beta

0.31

52-Week Price Change

67.11%

50-Day Moving Average

16.17

200-Day Moving Average

18.27

Relative Strength Index (RSI)

43.46

Average Volume (3m)

894.19K

Jade Biosciences upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 10, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

Apr 29, 2025

Jade Biosciences as a current ratio of 20.33, with Debt / Equity ratio of 0.22%

Current Ratio

20.33

Quick Ratio

20.33

Debt to Market Cap

0.00

Net Debt to EBITDA

0.69

Interest Coverage Ratio

0.00

In the past 12 months, Jade Biosciences has paid 58.00K in taxes.

Income Tax

58.00K

Effective Tax Rate

-0.00

Jade Biosciences EV to EBITDA ratio is -5.05, with an EV/FCF ratio of -6.39.

EV to Sales

0.00

EV to EBITDA

-5.05

EV to Free Cash Flow

-6.39

EV to Operating Cash Flow

-6.39

Jade Biosciences has $461.20M in cash and marketable securities with $628.00K in debt, giving a net cash position of $460.58M billion.

Cash & Marketable Securities

$461.20M

Total Debt

$628.00K

Net Cash

$460.58M

Net Cash Per Share

$7.24

Tangible Book Value Per Share

$7.21

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Jade Biosciences is $50.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$50.50

Price Target Upside

235.77% Upside

Analyst Consensus

Strong Buy

Analyst Count

10

Revenue Growth Forecast

―

EPS Growth Forecast

91.41%

Smart Score

5

AI Score

45